Pacific Biosciences reported a 14% year‑over‑year revenue increase in Q4, attributing gains to expanded adoption by clinical customers and stronger demand in Europe. The company said consumables revenue reached a record and that instrument shipments of Revio and Vega contributed to product revenue growth. CEO Christian Henry noted a shift toward clinical applications such as whole‑genome sequencing for rare disease. PacBio also highlighted an upcoming cost‑focused product, SPRQ‑Nx, intended to lower sequencing costs and broaden market penetration. While instrument revenue softened in some markets due to constrained academic budgets, PacBio’s commercial and clinical traction positions the firm to capitalize on diagnostics and clinical sequencing momentum into 2026.